Organic cation transporter 3 and the dopamine transporter differentially regulate catecholamine uptake in the basolateral amygdala and nucleus accumbens.
cocaine
corticosterone
dopamine
release
uptake
voltammetry
Journal
The European journal of neuroscience
ISSN: 1460-9568
Titre abrégé: Eur J Neurosci
Pays: France
ID NLM: 8918110
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
29
08
2019
revised:
28
03
2020
accepted:
24
04
2020
pubmed:
30
7
2020
medline:
22
6
2021
entrez:
30
7
2020
Statut:
ppublish
Résumé
Regional alterations in kinetics of catecholamine uptake are due in part to variations in clearance mechanisms. The rate of clearance is a critical determinant of the strength of catecholamine signaling. Catecholamine transmission in the nucleus accumbens core (NAcc) and basolateral amygdala (BLA) is of particular interest due to involvement of these regions in cognition and motivation. Previous work has shown that catecholamine clearance in the NAcc is largely mediated by the dopamine transporter (DAT), but clearance in the BLA is less DAT-dependent. A growing body of literature suggests that organic cation transporter 3 (OCT3) also contributes to catecholamine clearance in both regions. Consistent with different clearance mechanisms between regions, catecholamine clearance is more rapid in the NAcc than in the BLA, though mechanisms underlying this have not been resolved. We compared the expression of DAT and OCT3 and their contributions to catecholamine clearance in the NAcc and BLA. We found DAT protein levels were ~ 4-fold higher in the NAcc than in the BLA, while OCT3 protein expression was similar between the two regions. Immunofluorescent labeling of the two transporters in brain sections confirmed these findings. Ex vivo voltammetry demonstrated that the magnitude of catecholamine release was greater, and the clearance rate was faster in the NAcc than in the BLA. Additionally, catecholamine clearance in the BLA was more sensitive to the OCT3 inhibitor corticosterone, while clearance in the NAcc was more cocaine sensitive. These distinctions in catecholamine clearance may underlie differential effects of catecholamines on behavioral outputs mediated by these regions.
Identifiants
pubmed: 32725894
doi: 10.1111/ejn.14927
pmc: PMC7775350
mid: NIHMS1628053
doi:
Substances chimiques
Catecholamines
0
Cations
0
Dopamine Plasma Membrane Transport Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
4546-4562Subventions
Organisme : NIAAA NIH HHS
ID : P50 AA026117
Pays : United States
Organisme : NIAAA NIH HHS
ID : P50 AA12298125
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA023999
Pays : United States
Organisme : NIAAA NIH HHS
ID : T32 AA007565
Pays : United States
Organisme : NIAAA NIH HHS
ID : P01 AA021099
Pays : United States
Organisme : NIDA NIH HHS
ID : F31 DA035558
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA014030
Pays : United States
Organisme : SRJ
ID : P50 DA0066
Organisme : NIDA NIH HHS
ID : R01 DA048490
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA014091
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA032895
Pays : United States
Organisme : NIDA NIH HHS
ID : P50 DA006634
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA041349
Pays : United States
Informations de copyright
© 2020 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.
Références
Behav Neurosci. 2015 Aug;129(4):450-6
pubmed: 26098230
Neuropharmacology. 2017 Nov;126:281-291
pubmed: 28666811
J Neurochem. 2006 Jan;96(2):473-81
pubmed: 16336224
Neuropsychopharmacology. 2018 Nov;43(12):2408-2417
pubmed: 29773909
Neuroscience. 2012 Jan 10;201:252-66
pubmed: 22100273
Neuropharmacology. 2007 Jun;52(8):1596-605
pubmed: 17459426
Neuroscience. 2013 Jan 3;228:395-408
pubmed: 23103792
Neuroscience. 2007 Jan 19;144(2):616-22
pubmed: 17110048
Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5880-4
pubmed: 7597046
Am J Addict. 2015 Sep;24(6):546-53
pubmed: 26249027
J Neurosci. 2004 Mar 17;24(11):2846-51
pubmed: 15028779
Am J Physiol Heart Circ Physiol. 2015 Dec 1;309(11):H1904-14
pubmed: 26432838
J Neurosci Methods. 2001 Dec 15;112(2):119-33
pubmed: 11716947
Neuroscience. 2006;138(2):703-14
pubmed: 16427744
Neuropharmacology. 2006 Jun;50(8):941-52
pubmed: 16581093
Neuropsychopharmacology. 1999 Jan;20(1):60-80
pubmed: 9885786
Drug Alcohol Depend. 2015 May 1;150:24-30
pubmed: 25765483
J Neurosci. 2003 Mar 15;23(6):2008-13
pubmed: 12657658
Synapse. 1995 Jul;20(3):269-79
pubmed: 7570359
BMC Endocr Disord. 2014 Nov 26;14:91
pubmed: 25425285
J Chem Neuroanat. 2013 Sep;52:36-43
pubmed: 23694905
Neuroscience. 2007 May 25;146(3):1193-211
pubmed: 17408864
ACS Chem Neurosci. 2010 Mar 12;1(6):450-462
pubmed: 20567609
Behav Brain Res. 2015;287:187-95
pubmed: 25823760
Membr Biochem. 1987-1988;7(2):87-106
pubmed: 3454391
J Neurosci Methods. 2011 Nov 15;202(2):158-64
pubmed: 21392532
Neuropharmacology. 2016 Feb;101:471-9
pubmed: 26525189
Stress. 2015;18(2):143-8
pubmed: 25758939
J Comp Neurol. 2009 Feb 1;512(4):529-55
pubmed: 19025979
Psychoneuroendocrinology. 2015 Jan;51:68-79
pubmed: 25286225
Behav Neurosci. 2009 Dec;123(6):1185-96
pubmed: 20001103
J Pharmacol Exp Ther. 1988 Jul;246(1):282-6
pubmed: 2839666
Biol Psychiatry. 1999 Aug 1;46(3):303-11
pubmed: 10435196
Soc Cogn Affect Neurosci. 2015 Sep;10(9):1161-8
pubmed: 25552573
Int J Neuropsychopharmacol. 2016 Apr 29;19(5):
pubmed: 26625893
Neuroscience. 2006;138(1):235-43
pubmed: 16359808
Endocrinology. 2016 Jun;157(6):2346-55
pubmed: 27054552
Brain Res Brain Res Rev. 1998 May;26(2-3):148-53
pubmed: 9651511
Chin J Integr Med. 2013 May;19(5):323-9
pubmed: 23674109
J Neurosci. 2006 Aug 23;26(34):8758-66
pubmed: 16928864
J Neurosci. 2010 Nov 10;30(45):15185-95
pubmed: 21068324
Brain Struct Funct. 2017 May;222(4):1913-1928
pubmed: 27659446
Neuroscience. 2009 Apr 10;159(4):1264-73
pubmed: 19344638
Biol Psychiatry. 1989 Dec;26(8):829-41
pubmed: 2590694
Nature. 1996 Feb 15;379(6566):606-12
pubmed: 8628395
Behav Brain Res. 2016 Sep 15;311:279-286
pubmed: 27247143
Analyst. 2003 Dec;128(12):1413-9
pubmed: 14737224
Neuroscience. 1998 Mar;83(1):81-91
pubmed: 9466400
Front Neural Circuits. 2013 Oct 11;7:152
pubmed: 24130517
J Neurochem. 2015 Sep;134(5):833-44
pubmed: 26011081
Neuropsychopharmacology. 1992 Nov;7(3):213-24
pubmed: 1388645
Brain Res. 2012 May 3;1452:47-60
pubmed: 22464880
Mol Psychiatry. 2002;7(1):21-6
pubmed: 11803442
Physiol Behav. 1988;43(1):47-55
pubmed: 3413250
J Neurosci. 2002 May 15;22(10):RC222
pubmed: 12006604
Anal Chem. 2013 Jul 2;85(13):6421-8
pubmed: 23706095
Neuroscience. 2015 Jan 22;284:854-864
pubmed: 25451295
Psychopharmacology (Berl). 2008 Jan;195(4):517-25
pubmed: 17879088
Neuropharmacology. 2014 Nov;86:228-40
pubmed: 25107591
J Neurochem. 2010 Jul;114(1):142-9
pubmed: 20402963
Psychoneuroendocrinology. 2013 Feb;38(2):300-5
pubmed: 22776419
Am J Respir Cell Mol Biol. 2005 Jul;33(1):79-88
pubmed: 15817714
Eur J Neurosci. 2015 Jan;41(1):31-44
pubmed: 25306895
Neuropsychopharmacology. 2011 Apr;36(5):1090-103
pubmed: 21270771
Brain Res. 1994 Mar 21;640(1-2):105-12
pubmed: 8004437
Psychoneuroendocrinology. 2013 Dec;38(12):3128-38
pubmed: 24103891
Prog Brain Res. 2000;125:179-90
pubmed: 11098656
J Pharmacol Exp Ther. 2010 Dec;335(3):743-53
pubmed: 20858707
Front Integr Neurosci. 2014 Jul 15;8:56
pubmed: 25076876
J Psychopharmacol. 2012 Apr;26(4):564-74
pubmed: 21628344
Neuropsychopharmacology. 2016 Aug;41(9):2263-74
pubmed: 26860203
Brain Res. 1994 Sep 19;657(1-2):42-50
pubmed: 7820642
J Neurochem. 2004 Oct;91(1):49-56
pubmed: 15379886
Eur J Neurosci. 2010 Nov;32(10):1735-43
pubmed: 21044174
J Neurosci. 2000 Dec 15;20(24):9333-40
pubmed: 11125013
Behav Brain Res. 2013 Jun 1;246:63-8
pubmed: 23458740
J Neurochem. 1995 Jun;64(6):2581-9
pubmed: 7760038
J Neurochem. 2004 Nov;91(3):683-93
pubmed: 15485498
Behav Brain Res. 2004 Aug 31;153(2):383-7
pubmed: 15265633
Drug Alcohol Rev. 2015 May;34(3):242-51
pubmed: 25735200
Parkinsonism Relat Disord. 2003 Jan;9(3):145-50
pubmed: 12573869
ACS Chem Neurosci. 2017 Feb 15;8(2):281-289
pubmed: 27936579
Behav Pharmacol. 2015 Feb;26(1-2):200-16
pubmed: 25426580
Brain Res. 1999 Dec 11;850(1-2):127-35
pubmed: 10629756
J Pharmacol Exp Ther. 2014 Aug;350(2):322-9
pubmed: 24917543
J Trauma Stress. 2007 Oct;20(5):833-44
pubmed: 17955535
Eur J Neurosci. 2008 Mar;27(6):1525-33
pubmed: 18336564
J Neurosci. 2013 Jul 17;33(29):11800-10
pubmed: 23864669
Neurochem Int. 2019 Feb;123:46-49
pubmed: 30055194
Br J Pharmacol. 1970 Nov;40(3):528-30
pubmed: 5497802
ACS Chem Neurosci. 2015 Jan 21;6(1):27-36
pubmed: 25491345
Neurochem Res. 2008 Aug;33(8):1618-33
pubmed: 18473172
Br J Pharmacol. 1969 Nov;37(3):638-49
pubmed: 5348467
J Neural Transm (Vienna). 2000;107(10):1149-57
pubmed: 11129104
Nat Neurosci. 1998 Sep;1(5):349-51
pubmed: 10196521
Neuropsychopharmacology. 2017 Feb;42(3):757-765
pubmed: 27604564
J Neurosci Res. 2003 Mar 1;71(5):701-9
pubmed: 12584728
Behav Pharmacol. 2014 Sep;25(5-6):473-92
pubmed: 25083570
Neuroscience. 2014 Dec 12;282:23-48
pubmed: 24735820
Psychopharmacology (Berl). 2016 Apr;233(8):1435-43
pubmed: 26892380
Synapse. 2001 Dec 1;42(3):185-92
pubmed: 11746715
Synapse. 2013 Oct;67(10):668-77
pubmed: 23564231
Eur J Neurosci. 2017 Nov;46(10):2638-2646
pubmed: 28965353